Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.71−0.21 (-1.92%)
Close on Nov 17, 2026Market cap $654.78MP/E –Yield –
Janux Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Janux Therapeutics's price to sales ratio was 31.5× on Nov 11, 2026, against 205.0× a year earlier. Over the last 5 years it ranged from 31.5× to 401.9×, with a median of 95.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 31.5× | −51.4 |
| 2025 | Dec 31, 2025 | 83.0× | −131.8 |
| 2024 | Dec 31, 2024 | 214.7× | +156.3 |
| 2023 | Dec 29, 2023 | 58.5× | −15.6 |
| 2022 | Dec 30, 2022 | 74.1× | −327.8 |
| 2021 | Dec 31, 2021 | 401.9× | – |
See a number that looks wrong?